GLP-1 receptor agonists and cardiovascular protection: A class effect or not?

Diabetes and Metabolism

Volumn 44, Issue 3, 2018, Pages 193-196

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Class effect; GLP 1 receptor agonist

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ALL CAUSE MORTALITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; EDITORIAL; FOLLOW UP; HEART PROTECTION; HUMAN; CARDIOVASCULAR SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS;

CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85043762831     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2017.12.009     Document Type: Editorial

References (45)

1. Brown, M.J., A rational basis for selection among drugs of the same class. Heart 89 (2003), 687–694.
2. Bailey, C.J., Metformin: historical overview. Diabetologia 60 (2017), 1566–1576.
3. Scheen, A.J., Hepatotoxicity with thiazolidinediones: is it a class effect?. Drug Saf 24 (2001), 873–888.
4. Tannen, R., Xie, D., Wang, X., Yu, M., Weiner, M.G., A new “Comparative effectiveness” assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf 22 (2013), 86–97.
5. Chan, S.P., Colagiuri, S., Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract 110 (2015), 75–81.
6. Singh, A.K., Singh, R., Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Rev Clin Pharmacol 9 (2016), 839–851.
7. Standl, E., Erbach, M., Schnell, O., Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect?. Curr Treat Options Cardiovasc Med, 16, 2014, 353.
8. Scheen, A.J., SGLT2 inhibitors: benefit/risk balance. Curr Diabetes Rep, 16, 2016, 92.
9. Filippas-Ntekouan, S., Filippatos, T.D., Elisaf, M.S., SGLT2 inhibitors: are they safe?. Postgrad Med 130 (2018), 72–82.
10. Mannucci, E., Monami, M., Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials. Adv Ther 34 (2017), 1–40.
11. Scheen, A.J., Delanaye, P., Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes Metab, 2017, 10.1016/j.diabet.2017.07.011 [Epub ahead of print, pii: S1262-3636(17)30548-7].
12. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
13. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
14. Kosiborod, M., Cavender, M.A., Fu, A.Z., Wilding, J.P., Khunti, K., Holl, R.W., et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
15. Ampudia-Blasco, F.J., Romera, I., Arino, B., Gomis, R., Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?. Int J Gen Med 10 (2017), 23–26.
16. Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Silverman, M.G., et al. DECLARE-TIMI 58: design and baseline characteristics. Diabetes, 66, 2017, A333 [Abstract 1245-P].
17. Bethel, M.A., Patel, R.A., Merrill, P., Lokhnygina, Y., Buse, J.B., Mentz, R.J., et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6 (2018), 105–113.
18. Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
19. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
20. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
21. Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
22. Monami, M., Zannoni, S., Pala, L., Silverii, A., Andreozzi, F., Sesti, G., et al. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. Int J Cardiol 240 (2017), 414–421.
23. Bonnet, F., Scheen, A.J., Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. Diabetes Metab 43 (2017), 299–313.
24. Scheen, A.J., GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab, 43, 2017 [2S13-2S9].
25. Mahmoud, A.N., Saad, M., Mansoor, H., Elgendy, A.Y., Barakat, A.F., Abuzaid, A., et al. Cardiovascular safety of incretin-based therapy for type 2 diabetes: a meta-analysis of randomized trials. Int J Cardiol 230 (2017), 324–326.
26. Savarese, G., Lund, L.H., Rosano, G.M.C., Incretin-based therapy for type 2 diabetes: a real class effect?. Int J Cardiol 227 (2017), 141–142.
27. Scheen, A.J., Cardiovascular outcome studies with incretin-based therapies: comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 127 (2017), 224–237.
28. Nauck, M.A., Meier, J.J., Cavender, M.A., Abd El Aziz, M., Drucker, D.J., Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136 (2017), 849–870.
29. Rao, G., Lopez-Jimenez, F., Boyd, J., D'Amico, F., Durant, N.H., Hlatky, M.A., et al. Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the American Heart Association. Circulation 136 (2017), e172–e194.
30. Taylor, S.I., GLP-1 receptor agonists: differentiation within the class. Lancet Diabetes Endocrinol 6 (2018), 83–85.
31. McAlister, F.A., Laupacis, A., Wells, G.A., Sackett, D.L., Users’ Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 282 (1999), 1371–1377.
32. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
33. Furberg, C.D., Class effects and evidence-based medicine. Clin Cardiol 23 (2000), IV15–IV19.
34. Soares, I., Carneiro, A.V., Drug class effects: definitions and practical applications. Rev Port Cardiol 21 (2002), 1031–1042.
35. Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
36. Dalsgaard, N.B., Vilsboll, T., Knop, F.K., Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons. Diabetes Obes Metab 20 (2018), 508–519.
37. Buse, J.B., Nauck, M., Forst, T., Sheu, W.H., Shenouda, S.K., Heilmann, C.R., et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381 (2013), 117–124.
38. Ahmann, A.J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes care 41 (2018), 258–266.
39. Rendell, M.S., Albiglutide: a unique GLP-1 receptor agonist. Expert Opin Biol Ther 16 (2016), 1557–1569.
40. Scheen, A.J., Dulaglutide for the treatment of type 2 diabetes. Expert Opin Biol Ther 17 (2017), 485–496.
41. Fisher, M., Petrie, M.C., Ambery, P.D., Donaldson, J., Ye, J., McMurray, J.J., Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 3 (2015), 697–703.
42. Scheen, A.J., Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol 3 (2015), 667–669.
43. Ferdinand, K.C., Botros, F.T., Atisso, C.M., Sager, P.T., Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a prespecified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 15, 2016, 38.
44. Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Diaz, R., Lakshmanan, M., Pais, P., et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obesity Metab 20 (2018), 42–49.
45. Scheen, A.J., Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. Lancet Diabetes Endocrinol 5 (2017), 236–238.